Aligos Therapeutics, Inc. SEC Filings

This Schedule 13G discloses that Sio Capital Management, LLC beneficially owned 355,937 shares of Aligos Therapeutics common stock, representing 5.49% of the class. The filing states these shares are held by affiliated funds for which Sio acts as a registered investment adviser, and that Sio has shared voting and shared dispositive power over the reported shares while having no sole voting or dispositive power. The percentage is calculated using 6,114,801 shares outstanding as reported in the issuer's 10-Q. Item 10 certifies the position was acquired and is held in the ordinary course of business and not to influence control. The filing also notes that Sio and its GP are controlled by Michael Castor, though any beneficial ownership by the GP or Mr. Castor is expressly disclaimed.

Adage Capital Management, L.P., together with reporting persons Robert Atchinson and Phillip Gross, disclosed beneficial ownership of 210,000 shares of Aligos Therapeutics common stock, representing 3.90% of the outstanding class on the basis indicated in the filing. The position includes 70,000 shares issuable upon exercise of warrants. The filing shows no sole voting or dispositive power and reports the stake as held with shared voting and dispositive power. The certifying statement indicates the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.

Aligos Therapeutics (ALGS) Q2-25 Form 10-Q shows a capital-strengthening quarter driven by its February 2025 $105 million PIPE financing. Net proceeds of $101.4 million and the re-measurement of 2023 warrants (-$63.2 million liability) swung stockholders’ equity from a $(29.0) million deficit at 12/31/24 to $101.9 million at 6/30/25. Shares outstanding rose to 6.15 million (post 1-for-25 split).

Liquidity: Cash & cash equivalents fell to $18.7 million, but short-term U.S. Treasury holdings increased to $104.3 million, lifting total liquid resources to $122.9 million. Management states this provides >12-month runway.

Operations: The company remains pre-commercial. Customer revenue was $1.3 million YTD (-27% YoY) tied to Amoytop R&D services. Six-month R&D expense fell 24% YoY to $28.5 million; G&A dropped 19% to $10.6 million. Operating loss narrowed to $37.8 million (vs. $48.5 million). However, after the warrant fair-value gain and $2.1 million interest income, YTD net income reached $27.2 million (prior-year loss $29.8 million).

Cash flow: OCF was -$36.4 million; capex minimal. Financing inflow of $101.6 million (PIPE & ESPP) offset $83.5 million deployed into Treasuries.

• 2025 PIPE issued 2.10 million shares, 1.92 million pre-funded warrants and 2.01 million common warrants (exercise $26.02; expiry 2032).
• Authorized share cap raised to 100 million voting and 15.8 million non-voting shares.
• Phase 2 CAM-E candidate ALG-000184 B-SUPREME trial has begun enrollment; interim read-out expected 2026.

Outlook: Aligos projects current cash to fund ≥12 months of R&D. Future value hinges on clinical read-outs and additional financings; no commercial revenue is expected near term.

Aligos Therapeutics (ALGS) filed a routine Form 4 disclosing that director Carole Nuechterlein received a stock option grant for 5,860 common shares on 06/25/2025 at an exercise price of $7.63 per share. The option will vest 100% on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2026 annual shareholders meeting, contingent upon her continued board service.

No shares were bought or sold and no other material transactions or changes in beneficial ownership were reported.